Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cerebral infarction after fractionated stereotactic radiation therapy of benign anterior skull base tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The influence on survival of glucocorticoid induced diabetes in cancer patients with metastatic spinal cord compression

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Survival and failure types after radiation therapy of vulvar cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Forecasting lung cancer incidence, mortality, and prevalence to year 2030

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Iatrogenic cerebral radiation necrosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. No changes in myocardial perfusion following radiation therapy of left-sided breast cancer: A positron emission tomography study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Safety and clinical feasibility of injecting a novel liquid fiducial marker for use in image guided radiotherapy in 15 patients with non-small cell lung cancer are reported. No major safety or toxicity issues were encountered. Markers present at start of radiotherapy remained visible in cone beam computed tomography and fluoroscopy images throughout the treatment course and on computed tomography images during follow-up (0-38 months). Marker volume reduction was seen until 9 months after treatment, after which no further marker breakdown was found. No post-treatment migration or marker related complications were found.

OriginalsprogEngelsk
TidsskriftClinical and Translational Radiation Oncologi
Vol/bind13
Sider (fra-til)24-28
Antal sider5
ISSN2405-6308
DOI
StatusUdgivet - nov. 2018

ID: 55856519